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Abstract
Some drugs cause phototoxicity in humans when exposed to light, thus there is a need for an in vivo phototoxicity
test to evaluate them. However, an in vivo phototoxicity test method to evaluate this has not been established. This
study aimed to establish an in vivo phototoxicity test method for transdermally administered drugs. For this, we
evaluated the phototoxicity using Sprague-Dawley (SD) rats for transdermal administered drugs and we studied the
appropriate UVA dose using 8-methoxypsalen, which is a well-known phototoxic drug. We found that a UVA dose
of 15 J/cm2 was dose and time dependent response compared to other UVA doses. We performed the Minimum
Erythema Dose (MED) test because UVB can cause skin irritation by itself and selected 0.01 J/cm2 as an appropriate
dose of UVB. Using the selected UVA and UVB doses, we performed a phototoxicity study of 6 pharmaceutical
drugs, which included phototoxic and non-phototoxic drugs. As a result of the phototoxicity test, 100% accuracy
was obtained when compared with previous studies. In addition, we performed histopathology to confirm the new
findings. We found that histopathology can be used as an additional indicator of phototoxicity test for
transdermally administered drugs.
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Introduction
Sunlight is comprised of visible light, infrared light, and
ultraviolet light, each with a different range of wave-
lengths. Ultraviolet light has a shorter wavelength than
visible light, has high energy, and a strong chemical action.
It can cause various phototoxic reactions, including acute
reactions such as erythema on the skin, as well as chronic
reactions such as photoaging. Phototoxicity is mainly in-
duced by exposure of photoreactive chemicals to ultravio-
let rays [1]. These compounds are chemically activated by
ultraviolet rays and bind to DNA in the cell nucleus, or
act on oxygen to form oxygen radicals or singlet oxygen
molecules, which affect skin cells. Skin exposed to UV rays
may exhibit symptoms such as erythema, eschar forma-
tion, edema, itchiness, stinging, and in severe cases, blis-
tering or pigmentation may occur [1].
In addition, chemicals such as psoralen, quinolone-
based antibiotics, anti-inflammatory drugs, and antide-
pressants among pharmaceuticals are reported to induce
phototoxicity. Studies such as these are important in the
evaluation and regulation of phototoxicity in pharma-
ceuticals [2–7]. The demand for evaluation of the photo-
toxicity evaluation of drugs is increasing, and the
International Council for Harmonisation of Technical
Requirements for Pharmaceuticals for Human Use
(ICH) has established the Photosafety Evaluation of
Pharmaceuticals (ICH S10), which presents general
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considerations for internationally agreed phototoxicity
evaluation in Guidance on Nonclinical Safety Studies for
the Conduct of Human Clinical Trials and Marketing
Authorization for Pharmaceuticals (ICH M3, R2) [8, 9].
However, ICH S10 doesn’t describe a specific method of
in vivo testing for evaluation of phototoxicity, so an
in vivo testing method is necessary.
Selection of appropriate UV irradiation conditions is
critical for both in vitro and in vivo phototoxicity testing.
UVA doses ranging from 5 to 20 J/cm2 are successfully
used in current phototoxicity testing, according to ICH
S10. UVA penetrates deeper than the epidermis and
reaches the capillaries, but UVB is limited to the epider-
mis. Therefore, in order to testing transdermal drugs,
the Minimum Erythema Dose (MED) test should be per-
formed to select the minimum UVB dose with no ery-
thema observed. In addition, the evaluation of in vivo
phototoxicity is based on skin reaction of the skin, which
is subjective and may vary depending on the tester be-
cause it relies on a gross examination method. There-
fore, we suggest the selection of an appropriate dose of
light for an in vivo phototoxicity test and the possibility




The phototoxic drugs 8-Methoxy psoralen (8-MOP),
Ibuprofen (IBF), Benzoyl peroxide (BPO), Ketoprofen
(KPF), and Piroxicam (PXC) were used as positive sub-
stances and the non-phototoxic drug Sulisobenzone
(SBZ) was used as a negative substance. A total of 6 sub-
stances were tested, and Acetone: DMSO (10:1) was
used as the vehicle control (V.C). On the day of the test,
test substances were prepared and the concentration of
the substance was chosen as the highest concentration
of soluble in vehicle control. 8-MOP, IBF, BPO, KPF,
PXC, and SBZ were purchased from Sigma-Aldrich (St.
Louis, MO, USA). All other reagents and materials were
purchased from commercial sources.
Animals
Six-week-old female SpragueDawley (SD) rats (135–150
g, body weight) were purchased from Koatech (Pyeong-
taek, Korea) and acclimated at an animal facility in the
Korea Ministry of Food and Drug Safety (Certification
Number: 1501MFDS08) in accordance with the Associ-
ation for Assessment and Accreditation of Laboratory
Animal Care (AAALAC) International Animal Care Pol-
icies (Accredited Unit, MFDS: Unit No. 001492). The
animals were acclimated for at least 5 days prior to ex-
perimentation. During the acclimation period, clinical
signs were checked once every day. SD rats were housed
in polycarbonate cages with free access to food and
water, and maintained on a 12 h dark/light cycle in a
room with controlled temperature at 22 ± 1 °C and with
relative humidity of 50 ± 10%.
Irradiation conditions
A UV irradiation device (Bio-Spectra, Vilber lourmat,
Germany) equipped with a UV tube (T-40.L, Vilber lour-
mat, Germany) was used as a light source. The UVA
lamp, emitting 320–380 nm wavelengths, was used at an
intensity of 2.2 mW/cm2. The UVB lamp, emitting 290–
320 nm wavelengths, was used at an intensity of 2.2
mW/cm2. In addition, the light irradiation intensity was
checked using a UVP UVX radiometer (UVP, USA),
UVP UVX-36 (UVP, USA), UVX-31 (UVP, USA).
Preparation of animals
One day before the test, rats were separated into groups
and shaved. Weight variation did not exceed 20% of the
mean weight and the rats were randomly separated into
the test groups according to body weight. Three rats per
group were used, and the rat number was assigned to
‘test number-individual number’. Rats with abnormal
skin lesions were excluded from the test. Rats were anes-
thetized intraperitoneally using sodium pentobarbital
(30 mg/kg), and the hair of rats on the entire back of
each rat was shaved with clippers. For convenience of
observationof irradiation and phototoxic reaction, the ir-
radiation site of the entire back of each rat was divided
into 4 sites and spotted at 1.5 × 1.5 cm2 using a skin
marker. Except for this site, the aluminum foil was used
to block the light. The same procedures were performed
on the non-irradiated group as were performed on the
irradiated group.
Minimum erythema dose (MED) test
The rats were irradiated with 0.01, 0.03, 0.05, 0.1, 0.15,
0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5 J/cm2 UVB. After 24, 48,
and 72 h of irradiation, phototoxic skin reactions (ery-
thema/eschar and edema) were evaluated and scored ac-
cording to Draize’s method (Table 1).
Irradiation dose selection test
This test was performed by transdermal administration
of 8-MOP, which was prepared on the day of the test.
We used the highest concentration of drug that was sol-
uble in the vehicle control. The concentration of the test
substance is as follows: 8-MOP 0.0001, 0.001, 0.01 w/v
%. The test substances were treated 100 μl of 8-MOP so-
lution was applied to the application site (1.5 × 1.5 cm2)
on the back of the rat using a pipette. After 30 min of
treatment with 8-MOP, UV irradiation was performed
(UVA 5, 10, 15, 20 J/cm2; UVB 0.01 J/cm2). After 24, 48,
72 h of irradiation, phototoxic skin reactions (erythema/
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eschar and edema) were evaluated and scored according
to Draize’s method (Table 1).
Phototoxicity test of tansdermal administration by gross
examination
Five positive substances (8-MOP 0.0001, 0.001, 0.01 w/v
%; BPO 0.1, 1, 10 w/v %; IBF 0.1, 10, 25 w/v %; KPF 4,
40, 80 w/v %; PXC 0.1, 1, 2 w/v %) and one negative sub-
stance (SBZ 1 w/v %) were administered transdermally.
The test substances were treated 100 μl of 8-MOP solu-
tion was applied to the application site (1.5 × 1.5 cm2)
on the back of the rat using a pipette. After 30 min of
substance treatment, UV irradiation was performed
(UVA 15 J/cm2 and UVB 0.01 J/cm2). After 24, 48, 72 h
of irradiation, phototoxic skin reactions (erythema/es-
char and edema) were evaluated and scored according to
Draize’s method (Table 1).
Skin reaction evaluation
After 24, 48, 72 h of irradiation, phototoxic skin reac-
tions (erythema/eschar and edema formation) were eval-
uated and scored according to Draize’s criteria (Table 1)
[10]. For each test group, the skin reaction scores (ery-
thema/ eschar and edema) of individual animals were
summed for each site and the mean score was calculated
according to the following equation:
Mean score = Total of erythema and edema scores/
Number of animals tested [1].
A tested substance was judged to be phototoxic if the
mean score of the UV-irradiated group or site was
higher than that of the non-irradiated group or site at
any observation period. In this study, no statistical ana-
lysis was performed.
Histopathology of phototoxicity test
Histopathology was performed with two representative
samples each of the phototoxic drug 8-MOP, BPO, and
KPF tests. On the last day of the test (72 h after irradi-
ation), the skin tissues of the rats were separated. Skin
tissues were attached to thick paper in a flat orientation
using a stapler, then fixed with 4% PFA, embedded in
paraffin, sectioned, stained with hematoxylin and eosin
(HE), and examined microscopically by a certified
pathologist.
Results
Minimum erythema dose (MED) test
The results of the phototoxic reaction induced by UVB
in SD rats are shown in Fig. 1. Phototoxic reactions were
observed at doses of 0.03, 0.05, 0.1, 0.15, 0.2, 0.25, 0.3,
0.35, 0.4, 0.45, 0.5 J/cm2 and no phototoxic reaction was
observed at any time point at 0.01 J/cm2. From these re-
sults, it was confirmed that the dose of irradiation that
the phototoxicity is not induced by UVB is 0.01 J/cm2 is
the MED for UVB. Therefore, this dose was used in the
irradiation dose selection test and the phototoxicity test
of transdermal administration were used.
Irradiation dose selection test
The phototoxic reactions induced by 5–20 J/cm2 of
UVA and 0.01 J/cm2 of UVB in SD rats are shown in
Fig. 2. As shown in Fig. 2a, erythema of the irradiated
site of V. C administration was observed at 20 J/cm2,
and edema was not observed at any concentration of 8–
MOP at 5 J/cm2, so dose-dependent results could not be
confirmed. Therefore 5 and 20 J/cm2 were excluded
from further selection of UVA irradiation dose. As
shown in Fig. 2b, the time-dependent tendency of the
phototoxic reaction could not be observed at 10 J/cm2,
Table 1 Evaluation of skin reactions (Draize’s Criteria)
Score for erythema/eschar formation:
0; No erythema
1; Very slight erythema (barely perceptible)
2; Well defined erythema
3; Moderate to severe erythema
4; Severe erythema (beet redness) to slight eschar formation (injuries in
depth)
Score for edema formation:
0; No edema
1; Very slight edema (barely perceptible)
2; Slight edema (edges of area well defined by definite raising)
3; Moderate edema (raised approximately 1 mm)
4; Severe edema (raised more than 1mm and extending beyond area
of exposure)
Fig. 1 Skin score of the minimum erythema dose test after 24, 48,
72 h of UVB 0.01, 0.03, 0.05, 0.1 J/cm2 in SD rats. Mean score = Total
of erythema and edema scores/Number of animals tested (n = 3)
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and the time-dependent tendency of both erythema and
edema was observed at 15 J/cm2. Based on these results,
we selected 15 J/cm2 as the appropriate UVA irradiation
dose to identify dose and time dependent results.
Phototoxicity test of tansdermal administration by gross
examination
The phototoxic reactions induced by 8-MOP, BPO, IBF,
KPF, PXC, SBZ with UVA 15 J/, UVB 0.01 J/cm2 irradi-
ation in SD rats are shown in Table 2 and Fig. 3 (Data
shows only high concentration). In the 8-MOP irradi-
ation group, erythema was observed at 0.0001 and 0.001
w/v %, and erythema, eschar and edema were observed
at 0.01 w/v %. In IBF (0.1, 10, 25 w/v %) and PXC (0.1, 1,
2 w/v %) irradiation group was observed erythema and
edema were observed at all concentrations. In the BPO
irradiation group, phototoxicity was not observed at 0.1
w/v % but erythema was observed at 1 and 10 w/v %. In
the KPF irradiation group (4, 40, 80 w/v %) was observed
erythema was observed at all concentrations and no
phototoxic reaction was observed in the SBZ irradiation
group (1 w/v %). No phototoxic reaction was observed in
the non-irradiation group in all substances. These results
were consistent with existing phototoxicity evaluation
results, it was confirmed that it is consistent with the re-
sults of this study.
Histopathology of phototoxicity test
Representative histopathological photographs of two
phototoxic drugs (BPO and KPF) are shown in Fig. 4.
Table 3 (Data shows only high concentration) summa-
rizes the findings. In the case of BPO and KPF, which
caused reactions that were ambiguous by gross examin-
ation, histopathology was performed to obtain accurate
results, and representative phototoxic substance 8-MOP
and V. C were also performed. In the V. C irradiation
Fig. 2 Skin score of irradiation dose selection test using 8-MOP in SD rats. a Dose-dependent skin reaction after 24 h of UVA 5, 10, 15, 20 J/cm2
administered with 8-MOP 0.01, 0.001, 0.0001 w/v %. b Time-dependent skin reaction after 24, 48, 72 h of UVA 10, 15 J/cm2 administered with 8-
MOP 0.01 w/v %. Data of non-irradiated group are not shown because no have scores. Mean score = Total of erythema and edema scores/
Number of animals tested (n = 3)
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group, histopathology showed no phototoxic reaction so
we observed unusual histopathological lesions. In the 8-
MOP irradiation group, the phototoxic reaction was ob-
served in the irradiated rats that received low and
medium concentrations. However, at high concentra-
tions of 8-MOP, the epidermis was thickened due to the
proliferation of the epidermal layer, and showed necrosis
of the stratum corneum. In the BPO irradiation group,
thickening of the epidermis was observed at low concen-
trations, and necrosis of the stratum corneum was
observed at high concentrations. In the KPF irradiation
group, necrosis of the stratum corneum was observed at
low, medium, and high concentrations. In the 8-MOP,
BPO, and KPF treated irradiated groups showed normal
histopathological lesions at all concentrations. Therefore
8-MOP, BPO, and KPF were judged to be phototoxic
drugs.
Discussion
In this study, in order to selected the appropriate UV ir-
radiation dose with an in vivo phototoxicity test and
confirmed the phototoxicity of various drugs by two skin
reaction evaluation methods. The UV irradiation dose
suggested by ICH S10 is 5–20 J/cm2, and the irradiation
dose used by other research groups varies. Some UVA
values used in other studies are 10.2 J/cm2 for guinea
pigs [11], 10 J/cm2 for guinea pigs [12], 30 J/cm2 for SD
rats [13–15], and 10 J/cm2 for SD rats [1]. Some UVB
values used in other studies are 0.3 J/cm2 for guinea pigs
[12], 0.18 J/cm2 for guinea pigs [16], 0.25 J/cm2 for
guinea pigs and 0.031 J/cm2 for SD rats [1].
In order to select appropriate UVA and UVB doses to
use in our phototoxicity test, an irradiation dose selec-
tion test (for UVA) and a MED test (for UVB) were per-
formed. We found that the appropriate irradiation dose
of UVA, dose and time-dependent response was 15 J/
cm2. As a result of the MED test, we found that the ap-
propriate irradiation dose of UVB dose not causing pho-
totoxic reaction was 0.01 J/cm2.
An in vivo transdermal phototoxicity test was per-
formed using six test substances at the selected doses of








UV(+) 8-MOP 0.01 2.3 1.3
IBF 25 1.6 0.3
BPO 10 0.6 0
KPF 80 1.3 0
PXC 2 1.6 0
SBZ 1 0 0
UV(−) 8-MOP 0.01 0 0
IBF 25 0 0
BPO 10 0 0
KPF 80 0 0
PXC 2 0 0
SBZ 1 0 0
There were three SD rats per group. No phototoxic response (erythema,
edema) was observed in the non-irradiation site at all time
Fig. 3 Photographs of the skin reactions after 48 h of UVA 15 J/cm2 and UVB 0.01 J/cm2 in SD rats administered with 8-MOP, IBF, BPO, KPF, PXC,
SBZ. Data shows only high concentration
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irradiation. Phototoxic reactions were observed with
the five positive drugs (8-MOP, BPO, IBF, KPF,
PXC) and judged as phototoxic drugs. No phototoxic
reactions were observed with the negative control
drug (SBZ) and judged as non-phototoxic drug. Pho-
totoxic reactions (erythema, eschar, edema) was ob-
served and scored according to Draize’s criteria
(Table 1) [1, 16, 17].
In addition, we performed histopathology as an add-
itional indicator of the phototoxicity test. We found
histopathological lesions, caused by drugs, in the skin
of rats treated with 8-MOP, BPO, and KPF. Thus, we
confirmed the possibility of using histopathology as
an additional indicator to supplement gross examin-
ation, which is the subjective reading of the phototox-
icity test. From this results, the proposed photosafety
evaluation on the basis of the in vivo phototoxicity
for transdermal drugs.
Recently, interest in the photosafety of drugs has in-
creased in both regulatory agencies and industry, and
regulatory agencies have recommended the implementa-
tion of the 3Rs principle (refinement, reduction, and re-
placement). Considering these trends, the proposed test
method would be useful for evaluating the in vivo pho-
totoxicity of drugs.
Conclusions
Through this study, we found that suitable the irradi-
ation doses in SD rats for testing the phototoxicity of
drugs were UVA 15 J/cm2 and UVB 0.01 J/cm2. In
addition, we showed that the use of histopathology as an
additional indicator in the evaluation of phototoxicity al-
lows more accurate and objective judgment. This con-
firmed the availability of the transdermal drug in vivo
photosafety test method.
Fig. 4 Representative histopathological photographs of SD rat skin reactions after 72 h of UVA 15 J/cm2 and UVB 0.01 J/cm2. a V. C irradiation site.
b 8-MOP 0.01 w/v % irradiation site. c BPO 10 w/v % irradiation site. d KPF 80 w/v % irradiation site





8-MOP 298–81-7 Phototoxic Phototoxic Phototoxic
IBF 15,687–27-1 Phototoxic Phototoxic Phototoxic
BPO 94–36-0 Phototoxic Weak-phototoxic Phototoxic
KPF 22,071–15-4 Phototoxic Weak-phototoxic Phototoxic
PXC 36,322–90-4 Phototoxic Phototoxic Phototoxic
SBZ 4056-45-6 Non-phototoxic Non-phototoxic Non-phototoxic
aData from Yonezawa et al. 2015 [1]
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